Taclonex® Topical Suspension is indicated for the topical treatment of plaque psoriasis of the scalp and body in patients 18 years and older.

Usual Dosage and Administration

Apply Taclonex® Topical Suspension to affected areas once daily for up to 8 weeks. Treatment may be discontinued earlier, if cleared.

Instruct patients not to exceed a maximum weekly dose of 100 g.

Important Administration Instructions

Instruct patients to shake bottle prior to using Taclonex® Topical Suspension and to wash their hands after applying the product. Taclonex® Topical Suspension is not for oral, ophthalmic, or intravaginal use.

Dosage Forms And Strengths

Topical Suspension, 0.005%/0.064%

Each gram of Taclonex® Topical Suspension contains 52.18 mcg of calcipotriene hydrate (equivalent to 50 mcg of calcipotriene) and 0.643 mg of betamethasone dipropionate (equivalent to 0.5 mg of betamethasone). Taclonex® Topical Suspension is a viscous, nearly odorless, almost clear, colorless to slightly off-white suspension.

Storage And Handling

Taclonex® Topical Suspension is a viscous, nearly odorless, almost clear, colorless to slightly off-white suspension. It is available in bottles of: 60 g (NDC 50222-501-06)

Storage

Store between 20°C-25°C (68°F-77°F); excursions permitted between 15°C-30°C (59°F-86°F). [See USP controlled room temperature.] Do not refrigerate. Keep the bottle in the outer carton when not in use. The product should be used within six months after it has been opened.

Handling

Shake before use. Keep out of reach of children

Manufactured by: LEO Laboratories Ltd. (LEO Pharma) 285 Cashel Road Dublin 12, Ireland. Distributed by: LEO Pharma Inc. 1 Sylvan Way, Parsippany, NJ 07054, USA 1-877-494-4536. Revised: 10/2012

Last reviewed on RxList: 10/29/2012
This monograph has been modified to include the generic and brand name in many instances.